- Home
- BDN vs PRAX Comparison
BDN vs PRAX Comparison
Compare BDN & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDN
- PRAX
- Stock Information
- Founded
- BDN 1986
- PRAX 2015
- Country
- BDN United States
- PRAX United States
- Employees
- BDN N/A
- PRAX N/A
- Industry
- BDN Real Estate Investment Trusts
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- BDN Real Estate
- PRAX Health Care
- Exchange
- BDN Nasdaq
- PRAX Nasdaq
- Market Cap
- BDN 799.6M
- PRAX 599.7M
- IPO Year
- BDN N/A
- PRAX 2020
- Fundamental
- Price
- BDN $4.11
- PRAX $38.06
- Analyst Decision
- BDN Hold
- PRAX Strong Buy
- Analyst Count
- BDN 1
- PRAX 10
- Target Price
- BDN $5.00
- PRAX $116.50
- AVG Volume (30 Days)
- BDN 2.5M
- PRAX 461.1K
- Earning Date
- BDN 04-22-2025
- PRAX 05-02-2025
- Dividend Yield
- BDN 14.44%
- PRAX N/A
- EPS Growth
- BDN N/A
- PRAX N/A
- EPS
- BDN N/A
- PRAX N/A
- Revenue
- BDN $312,538,000.00
- PRAX $8,122,000.00
- Revenue This Year
- BDN $57.03
- PRAX N/A
- Revenue Next Year
- BDN $3.55
- PRAX $789.73
- P/E Ratio
- BDN N/A
- PRAX N/A
- Revenue Growth
- BDN N/A
- PRAX 270.02
- 52 Week Low
- BDN $3.41
- PRAX $26.70
- 52 Week High
- BDN $6.54
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- BDN 51.96
- PRAX 52.58
- Support Level
- BDN $4.02
- PRAX $34.89
- Resistance Level
- BDN $4.25
- PRAX $40.89
- Average True Range (ATR)
- BDN 0.14
- PRAX 2.48
- MACD
- BDN 0.06
- PRAX 0.77
- Stochastic Oscillator
- BDN 75.00
- PRAX 65.09
About BDN Brandywine Realty Trust
Brandywine Realty Trust engaged in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science/lab, residential, and mixed-use properties. The company owned and managed properties within five segments. The Philadelphia CBD segment includes properties located in the City of Philadelphia in Pennsylvania. The Pennsylvania Suburbs segment includes properties in Chester, Delaware and Montgomery counties in the Philadelphia suburbs. The Austin, Texas segment includes properties in the City of Austin, Texas. The Metropolitan Washington, D.C. segment includes properties in Northern Virginia, Washington, D.C. and Southern Maryland. The Other segment includes properties in Camden County, New Jersey and New Castle County, Delaware.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.